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Abstract
Betaglycan is an accessory receptor for the transforming growth factor-b (TGFb) superfamily, many members of which play
key roles in kidney development. The purpose of this study was to define the role of this co-receptor on fetal murine kidney
development. Stereological examination of embryonic and adult betaglycan heterozygous kidneys revealed augmented
nephron number relative to littermate controls. Fetal heterozygous kidneys exhibited accelerated ureteric branching, which
correlated with augmented nephron development at embryonic day (e) 15.5. In contrast, betaglycan null kidneys exhibited
renal hypoplasia from e13.5 and reduced nephron number at e15.5. Quantitative real-time PCR analysis of e11.5–e14.5
kidneys demonstrated that heterozygous kidneys exhibited a transient decrease in Bmp4 expression at e11.5 and a
subsequent cascade of changes in the gene regulatory network that governs metanephric development, including
significant increases in Pax2, Eya1, Gdnf, Ret, Wnt4, and Wt1 expression. Conversely, gene expression in null kidneys was
normal until e13.5, when significant reductions were detected in the expression of Bmp4 as well as other key metanephric
regulatory genes. Tgfb1 and Tgfb2 mRNA expression was down-regulated in both nulls and heterozygotes at e13.5 and
e14.5. The opposing morphological and molecular phenotypes in betaglycan heterozygote and null mutants demonstrate
that the levels of betaglycan must be tightly regulated for optimal kidney development.
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Introduction
The development of the metanephros and the subsequent
establishment of nephron endowment begins when an outgrowth
from the Wolffian duct known as the ureteric bud, extends
towards and invades the metanephric mesenchyme [1]. Recip-
rocal interactions between the epithelial ureteric bud and the
surrounding metanephric mesenchyme result in branching
and extension of the ureteric tree, which generates the frame-
work of the collecting duct system of the adult kidney. At the
tips of the ureteric tree branches, mesenchymal condensation
and mesenchymal-to-epithelial transition occur giving rise to
nephrons [2].
The many processes involved in metanephric development are
tightly regulated by complex molecular regulatory networks [3].
Members of the TGFb superfamily of signalling molecules have
previously been shown both in vitro [4,5,6] and in vivo to regulate
key aspects of metanephric development [7,8,9,10,11,12]. At
embryonic day (e) 11.5, transcripts for the three TGFb isoforms
(Tgfb1–3), the type I (Tgfbr1) and II (Tgfbr2) TGFb signalling
receptors as well as transcripts for many other members of the
TGFb superfamily are present in the mouse kidney [11]. Of the
TGFb isoform null mouse lines, only Tgfb2 mutant mice exhibit
defects in kidney development [6,12,13,14]. These include
dysplastic ureteric tree formation, impaired glomerulogenesis
and renal agenesis [6,12]. In contrast, Tgfb2 heterozygous mice
exhibit accelerated metanephric development, which results in
augmented nephron endowment at postnatal day (PN) 30 [6].
These data indicate that TGFb2 plays complex, non-redundant
roles in the developing metanephros, and further understanding of
the factors that control TGFb2 action in the fetal kidney is
required.
Recent evidence suggests that the efficacy of TGFb isoforms in
tissue development depends on the presence or absence of specific
TGFb superfamily co-receptors such as the type III TGFb
receptor (TGFBR3), commonly referred to as betaglycan [15,16].
Betaglycan presents ligand to the type II TGFb receptor, an action
of particular importance for TGFb2, which does not bind to the
type II TGFb receptor with high affinity alone [15,17,18].
Additional studies have highlighted a more complex role for
betaglycan, which is now known also to directly bind inhibins
and certain BMPs through its core, while indirectly influencing
BMP and activin function through the regulation of inhibins
[19,20].
To define the role of this co-receptor in metanephric
development, we studied betaglycan heterozygous (betaglycan
+/2)
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2/2) mouse kidneys at the morphological and
molecular levels. We show that betaglycan mutant kidney
phenotypes are similar to the previously characterized Tgfb2
mutant phenotypes. Furthermore, we demonstrate that the
opposing phenotypes in the betaglycan
2/2 and betaglycan
+/2
kidneys arise from distinct alterations in the positive and negative
gene regulatory networks which govern fetal kidney forma-
tion. Collectively, our data indicate that the TGFb2/beta-
glycan signalling pathway has dosage-dependent actions within
the fetal kidney, and that this pathway must be tightly controlled
for normal branching morphogenesis and nephrogenesis to
occur.
Results
Betaglycan is expressed in the developing mouse kidney
At e11.5, betaglycan was localised to the ureteric epithelium,
with no specific immunostaining detected in the metanephric
mesenchyme (Figure 1A–B). By e14.5, betaglycan was detected in
developing pre-glomerular structures while remaining strongly
expressed in ureteric epithelium (Figure 1C–E). At this develop-
mental stage, expression was also observed in the interstitium
(Figure 1D) but was absent from the mesenchyme in the
nephrogenic zone (Figure 1E). At e16.5, betaglycan immunolo-
calization was similar to that seen at e14.5 (Figure 1F–G).
Betaglycan expression was not detected in the negative control,
e14.5 betaglycan null kidney (Figure 1H–J).
Contrasting developmental phenotypes in betaglycan
mutant metanephroi
Stereological analysis of e13.5 metanephroi identified a
significant 30–40% decrease in metanephric volume in betagly-
can
2/2 embryos compared to wildtype and betaglycan
+/2
embryos (Table 1). Likewise, absolute ureteric epithelial volume
was significantly decreased in betaglycan
2/2 mice (Table 1).
However, the relative volume of the ureteric epithelium was
comparable in all three groups. At e15.5, metanephric volume in
betaglycan
+/2 was significantly greater (30%) than in wildtype
embryos, which in turn were 49% larger than the kidneys of
betaglycan
2/2 embryos (Table 1). However, no differences in total
kidney weights or volumes were observed between wildtype and
betaglycan
+/2 at PN30 (Table 2).
Betaglycan
+/2 mice have augmented nephron
endowment at e15.5 and PN30
Analysisofnephronnumberate15.5revealedthat betaglycan
+/2
kidneys contained approximately 32% more PNA-positive struc-
tures than wildtype metanephroi (Table 1). In contrast, betagly-
can
2/2 metanephroi contained 32% fewer PNA-positive structures
than wildtype kidneys, and approximately half the number as
betaglycan
+/2 kidneys (Table 1). At PN30, kidneys from betagly-
can
+/2 mice contained 13,9606693 nephrons compared with
11,3956921 nephrons in age-matched wildtype kidneys (Table 2),
representing a 23% increase in total nephron number in
betaglycan
+/2 mice (p,0.0001). Augmented nephron endowment
was accompanied by significant decreases in mean glomerular
volumes (p,0.05). However, total glomerular and renal corpuscle
volumes were similar in the two groups (Table 1). No renal
histopathology was observed in either genotype at PN30 (data not
shown).
The length of nephrogenic period is normal in
betaglycan heterozygote mice
Analysis of e11.0 – e12.0 gonadal ridges indicated that the
emergence of the ureteric bud from the Wolffian duct commenced
in all three genotypes at the same embryonic stage (e11.0)
(Figure 2A–B). Between e11.5 and e12.0, the ureteric bud from
betaglycan
2/2 embryos exhibited the same number of branches as
wildtype ureteric bud. However, betaglycan
+/2 metanephroi
consistently exhibited an augmented number of ureteric tips at
this time, indicating extra ureteric branching had occurred
(Figure 2A–B). In vitro culture of whole metanephroi from e12.5
betaglycan mutant and wildtype embryos indicated that ureteric
branch (p,0.01) and tip number (p,0.01) were both significantly
greater in betaglycan
+/2 mice (27.4365.08: 34.2965.68) than in
wildtypes (21.8364.69: 27.4265.11; Figure 2C). The increased
ureteric tree development in betaglycan
+/2 mice correlated with a
significant increase (p,0.01) in the number of developing
glomeruli (38.6464.22) compared with wildtype metanephroi
(29.4265.26). In contrast, betaglycan
2/2 metanephroi exhibited
significantly fewer ureteric branches (11.2062.94; p,0.01), tips
(14.4063.72; p,0.01) and glomeruli (15.2064.92; p,0.01) than
both wildtype and betaglycan
+/2 metanephroi. Finally, histolog-
ical analysis of neonatal kidneys revealed that nephrogenesis was
Figure 1. Localisation of betaglycan in the developing mouse kidney. Betaglycan immunostaining (green fluorescence) in mouse kidney at
e11.5 (A–B); e14.5 (C–E) and e16.5 (F–G). Negative control, e14.5 betaglycan null metanephros (TO-PRO: H, Betaglycan: I, Merge: J). Arrows, ureteric
epithelium; M, metanephric mesenchyme; I, interstitial mesenchyme; diamonds, pre-glomerular structures; G, glomeruli; Oval, Bowman’s capsule; Red
fluorescence, TO-PRO nuclear staining. Scale bars =100 mm.
doi:10.1371/journal.pone.0018723.g001
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+/2 mice by PN5, as indicated
by absence of a nephrogenic zone (Figure 2D).
Metanephric signalling networks are disrupted in
betaglycan mutant mice
Early Ureteric Branching Morphogenesis. BMP4 and
GDNF, both members of the TGFb superfamily, play important
roles in regulating ureteric budding and ureteric branching
morphogenesis. Formation of the ureteric bud at approximately
e11.0 and subsequent ureteric branching morphogenesis both
require secreted GDNF from the metanephric mesenchyme to
bind with its cognate receptor RET, as well as inhibition of BMP4
at the ureteric bud site and around the ureteric tips. In accordance
with the increased ureteric branching observed in wholemount
urogenital ridges, betaglycan
+/2 mice exhibited significantly
decreased Bmp4 expression at e11.5 (p,0.01) while Gdnf
expression was significantly upregulated at e12.5 in comparison
to age-matched wildtype metanephroi (Figure 3A–B). These
changes in betaglycan
+/2 metanephroi were accompanied by
consistent increases in Ret expression from e12.5 (Figure 3C). In
contrast, betaglycan
2/2 metanephroi displayed wildtype-like
mRNA expression profiles for Bmp4, Gdnf and Ret at e11.5
(Figure 3A–C). However, from e12.5-e14.5, significant decreases
in the expression of both the inhibitory (Bmp4) and stimulatory
pathways (Gdnf/Ret) controlling renal branching morphogenesis
were detected in betaglycan
2/2 kidneys (Figure 3A–C).
Regulation of the Ret and GDNF Expression
Profile. GDNF signalling through RET is viewed as the
critical positive factor in branching morphogenesis [21,22].
Multiple studies have identified upstream transcriptional
regulators of Gdnf such as Pax2, Eya1 and Six1 as integral to
the induction of GDNF expression and in turn early metanephric
development [23,24,25,26]. The most important of these factors
appears to be Pax2, as Pax2 is not only critical for the initiation of
Gdnf expression but also in the enhancement of Ret expression in
the developing ureteric tree [23]. At e11.5, Pax2 expression, but
not Eya1 or Six1 expression, was significantly increased in
betaglycan
+/2 mutants (Figure 3D–F). At e12.5 and e13.5,
betaglycan
+/2 metanephroi displayed significant increases in
both Pax2 and Eya1 mRNA compared with age-matched
wildtype, with expression for both genes returning to wildtype
levels at e14.5 (Figure 3D–E). Betaglycan
2/2 metanephroi
displayed wildtype-like expression profiles of Pax2 and Eya1
until e13.5, after which time significant decreases in expression of
these genes was observed in betaglycan null metanephroi
compared to age-matched wildtype metanephroi.
Nephrogenesis. Wilm’s Tumor 1 (WT1) and Wingless-
related MMTV integration site 4 (WNT4) are both essential for
nephrogenesis [24,25,27,28]. Changes in mRNA expression for
Wt1 were observed from e12.5 with betaglycan
+/2 metanephroi
displaying consistently increased Wt1 expression and betaglycan
2/
2 metanephroi consistently decreased Wt1 expression from e13.5,
compared with age-matched wildtype metanephroi (Figure 3H).
Similar changes were observed in Wnt4 expression levels
(Figure 3G). These data suggest that dysregulation of glomerular
formation in betaglycan mutant mice is present from the
commencement of glomerulogenesis.
TGFb Isoforms. All three TGFb isoforms were detected in
wildtype metanephroi from e11.5, with an upregulation in Tgfb1
and Tgfb2 expression detected at e13.5–e14.5 (Figure 4). This
upregulation in Tgfb1 and Tgfb2 mRNA was not observed in
betaglycan mutant metanephroi, with both betaglycan
+/2 and
betaglycan
2/2 mutants displaying decreased expression levels of
these genes compared to wildtype littermates (p,0.01; Figure 4A–
B). Interestingly, the levels of Tgfb2 and betaglycan mRNA
expression appeared to be directly correlated, as Tgfb2 expression
at e13.5 and e14.5 was less in betaglycan
+/2 mutants than in
wildtype mice, and lessagain in betaglycan
2/2 mutants (Figure 4B).
Tgfb3 expression was similar in all three genotypes at all ages
examined (Figure 4C).
SMAD1 and SMAD3 signalling is unchanged in
betaglycan mutants
Transduction of TGFb superfamily signals involves the
phosphorylation of intracellular receptor associated proteins
known as SMADs. SMAD2 and SMAD3 are predominantly
associated with activation of TGFb/activin signalling pathways
Table 1. Stereological data for betaglycan wildtype, heterozygous and knockout mouse kidneys at e13.5 and e15.5.
+/+ +/2 2/2 p
e13.5 Vkid (mm
3) 0.10960.018
a 0.10360.021
a 0.07760.011
b ,0.001
Vue (mm
3) 0.01560.003
a 0.01560.003
a 0.01060.001
b 0.0013
%V ue of Vkid 13.5061.67
a 13.5660.39
a 12.5860.26
a 0.3
e15.5 Vkid (mm
3) 0.26160.034
a 0.34060.055
b 0.18760.005
c ,0.001
No. of PNA
+ve Structures 68611
a 90612
b 4768
c ,0.001
Values are mean 6 S.D. e13.5: (n) = +/+ (5), +/2 (9), 2/2 (6); e15.5: (n) =7 mice/genotype. Data were analysed via one-way ANOVA followed by a Tukey’s post-hoc
analysis. Those groups not sharing a common letter are significantly different (p,0.01).
doi:10.1371/journal.pone.0018723.t001
Table 2. Stereological analysis of female wildtype (+/+) and
betaglycan heterozygous (+/2) mouse kidneys at postnatal
day 30.
+/+ +/2
Body weight (g) 16.5261.66 16.4661.69
Kidney weight (g) 0.12060.024 0.12360.020
Kidney volume (mm
3) 94.6268.87 101.37618.35
Total glomerular number 113956921 139606693**
Mean glomerular volume (610
24 mm
3) 1.67860.151 1.31660.226*
Total glomerular volume (mm
3) 1.91060.375 1.84460.370
Mean renal corpuscle volume (610
24 mm
3) 2.27360.334 1.79560.320*
Total renal corpuscle volume (mm
3) 2.58660.341 2.51560.523
Values are mean 6 S.D. (n) =7 mice/genotype,
*p,0.05,
**p,0.0001.
doi:10.1371/journal.pone.0018723.t002
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[29,30]. As betaglycan can bind both TGFb and BMP ligands,
the altered expression of the co-receptor has the potential to
disrupt both pathways [20,31]. To determine whether TGFb or
BMP signal transduction was altered in betaglycan mutants,
phospho (p)SMAD1 and pSMAD3 immuno-stained cells were
counted in e13.5 metanephroi from betaglycan wildtype and
mutant embryos. This analysis illustrated that far fewer cells
exhibited pSMAD1 than pSMAD3 in all three genotypes.
However, no differences in the percentages of cells containing
activated pSMAD1 or pSMAD3 were found between genotypes
(Figure 5A–B).
Discussion
Despite considerable functional redundancy amongst TGFb
superfamily members in the developing kidney [11], morpholog-
ical and molecular defects were detected in betaglycan
+/2 and
betaglycan
2/2 kidneys. Tightly controlled betaglycan expression is
essential for normal metanephric development as partial or
complete ablation of expression results in opposing renal pheno-
types. In the betaglycan
+/2 kidney, changes in gene expression
were observed as early as e11.5. Notably, a decrease in Bmp4
expression at this time was observed in betaglycan
+/2 kidneys
compared with wildtype and betaglycan
2/2 kidneys. Although
BMP4 appears to have multiple roles in kidney development [32],
at the time of ureteric bud outgrowth, BMP4 activity in the sleeve
of metanephric mesenchyme surrounding the Wolffian duct must
be antagonized by an endogenous inhibitor, gremlin 1, for
budding to occur [10,33]. While the timing of ureteric budding
appears similar in the three genotypes, BMP4 can also act as an
inhibitor of GDNF/RET/WNT-mediated branching morpho-
genesis [10]. Therefore, the reduced expression of Bmp4 at e11.5 is
in accordance with the observed increase in ureteric branching at
this time. Interestingly, the level of renal Bmp4 mRNA expression
in betaglycan
+/2 mice after this time was not different to that of
age-matched wildtype mice. However, a cascade of changes in the
gene regulatory network governing metanephric development
followed in the betaglycan
+/2 kidney, including significant
increases in expression levels of Pax2, Eya1, Gdnf, Ret, Wnt4, and
Wt1. Of these genes, Pax2 was the first to be upregulated in the
betaglycan
+/2 kidney at e11.5, in keeping with its role in inducing
Figure 2. Effect of decreased endogenous betaglycan expression on metanephric development and glomerulogenesis. (A)
Representative images of developing metanephroi from wildtype (+/+), betaglycan heterozygous (+/2) and null (2/2) embryos with 14–17 tail
somites (e11.0), 18–22 tail somites (e11.5) and 23–26 tail somites (e12.5). Arrows, ureteric tips; scale bars =150 mm. (B) Total number of ureteric tips
present in +/+ (solid bars), +/2 (striped bars) and 2/2 (clear bars) developing metanephroi, at progressive developmental stages. n$5 genotype/
stage. (C) Wholemount immunofluorescent labelling of the ureteric tree (Calbindin D28K, green fluorescence) and developing glomeruli (WT1, red
fluorescence) in e12.5 betaglycan wildtype (+/+), heterozygous (+/2) and null (2/2) metanephroi following 48 h culture. (iv-vi) Quantification of
ureteric branch points, ureteric tips and glomeruli in betaglycan wildtype, heterozygous and null mice (n) = +/+ (12), +/2 (14), 2/2 (10). Scale bar
=250 mm. (D) Representative histological images of PN4 and PN5 kidneys from wildtype (+/+) and betaglycan heterozygous (+/2) mice (i-iv). Comma-
shaped (C) and S-shaped (S) bodies in a clearly defined nephrogenic zone (dotted line) (i,iii), or displaying mature glomeruli (G) and no nephrogenic
zone indicating cessation of nephrogenesis (ii,iv). Scale bars =100 mm. Values are mean 6 SD. Analysis via one-way ANOVA followed by Tukey’s post-
hoc analysis, across all genotypes and ages. Significant differences (p,0.05) between groups are represented by different letters.
doi:10.1371/journal.pone.0018723.g002
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such as Gdnf and Ret [23,34].
In contrast to betaglycan
+/2 kidneys, the rate of early branching
morphogenesis in betaglycan
2/2 metanephroi resembled that of
wildtypes. Accordingly, no differences in levels of gene expression
were found between null and wildtype kidneys at e11.5. At e12.5,
betaglycan
2/2 kidneys exhibited only small decreases in Ret
expression compared to wildtypes. However, at e13.5, expression
levels of several integral nephrogenic genes were significantly
reduced in betaglycan
2/2 kidneys compared to wildtype, and
these reductions correlated with the reduced kidney volume
observed in betaglycan
2/2 embryos at this time. These findings
indicate that a complete loss of betaglycan results in uncoupling of
the reciprocal inductive signalling pathways that operate between
the metanephric mesenchyme and ureteric epithelium to drive the
progression of branching morphogenesis and nephrogenesis. In
particular, genes that drive the Gdnf/Ret regulatory pathway, such
as Pax2, fail to be upregulated in the betaglycan
2/2 kidney, which
Figure 3. Betaglycan mutant renal mRNA expression. Quantitative real time PCR assessment of genes involved in metanephric development
using RNA derived from age-matched wildtype (solid bars), betaglycan heterozygous (striped bars) and betaglycan null (clear bars) metanephroi.
Values are mean + SEM. n=4–6 RNA pools/genotype/age. Analysis via one-way ANOVA followed by Tukey’s post-hoc analysis conducted separately
for each gene at each time point. Significant differences (p,0.05) between genotypes are represented by different letters.
doi:10.1371/journal.pone.0018723.g003
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hypoplastic renal phenotype at e13.5.
Importantly, the expression of Six1, an upstream regulator of
Gdnf, of similar hierarchal order to Eya1, remained similar between
all genotypes through out all developmental stages analysed.
Previously, direct interactions between Eya1 and Six1 have been
shown to be essential for the induction and upregulation of Gdnf
expression in the MM [26,35]. As Eya1, and not Six1 expression
was altered in betaglycan mutant metanephroi, it is possible to
suggest that the influence of betaglycan on downstream Gdnf
expression may be elucidated through perturbations to Eya1
expression and not that of Six1. It is also possible that the
conserved Six1 expression in betaglycan mutants may be
responsible for sufficient Gdnf expression induction to prevent
the manifestation of more severe renal phenotypes such as renal
agenesis in betaglycan
2/2 embryos [35].
Finally, loss or reduction of betaglycan expression resulted in
decreased Tgfb1 and Tgfb2 expression in the fetal kidney. This may
be due to reduced TGFb sensitivity in the betaglycan mutant
kidneys as TGFbs are well-recognized to auto-induce their own
expression by both transcriptional and post-transcriptional mech-
anisms [36,37]. A loss or reduction in betaglycan on the cell
surface may lead to decreased sensitivity to the TGFbs, which
could in turn reduce the level of TGFb auto-induction and
compound the effects of the loss of betaglycan. Indeed, in
betaglycan
2/2 kidneys, the collective reduction of several TGFb
superfamily inputs (TGFb1, TGFb2, BMP4) coupled with the
complete absence of betaglycan, a key determinant of cellular
TGFb sensitivity, may result in sub-threshold levels of TGFb
superfamily signalling, which may explain why betaglycan
2/2
kidneys exhibit hypoplasia rather than an even greater rate of
kidney development than seen in betaglycan
+/2 mice.
Is betaglycan essential as a TGFb co-receptor in the fetal
kidney?
As fetal metanephroi express several potential ligands of
betaglycan, the specific mechanisms by which diminished
betaglycan expression impacts kidney development are not yet
clear. However, several pieces of evidence suggest that betaglycan
is serving an essential role as a TGFb2 co-receptor during early
kidney development. Firstly, betaglycan expression is coincident
with the previously published expression pattern of TGFb2i n
murine metanephroi [4,11,38]. Betaglycan was localized in the
ureteric epithelium from the earliest stages of ureteric bud
formation, and from e14.5 was also detected in metanephric
mesenchyme and the epithelium of developing nephrons. TGFb2
is similarly expressed by the ureteric epithelium, with expression
also detected in neighbouring tissues after e14.5 [38]. The expres-
sion of betaglycan in the ureteric epithelium at e11.0–e11.5 and
Figure 4. Expression of TGFb isoforms in kidneys of betaglycan mutant mice. Quantitative real time-PCR assessment of (A) Tgfb1; (B) Tgfb2;
and (C) Tgfb3 using RNA derived from age-matched wildtype (solid bars), betaglycan heterozygous (striped bars), and betaglycan null (clear bars)
metanephroi. Values are mean + SEM. n=4–6 RNA pools/genotype/age. Analysis via one-way ANOVA followed by Tukey’s post-hoc analysis
conducted separately for each gene at each time point. Significant differences (p,0.05) between genotypes are represented by different letters.
doi:10.1371/journal.pone.0018723.g004
Figure 5. SMAD1 and SMAD3 activation in betaglycan mutant metanephroi. Quantitative analysis of nuclear pSMAD1 and pSMAD3
expression per microscopic field in wildtype (solid bars), betaglycan heterozygous (striped bars) and betaglycan null (clear bars) metanephroi. n=4
metanephroi per genotype, with a minimum of 5 fields of view per metanephros. Values are mean + SD. Analysis via one-way ANOVA followed by
Tukey’s post-hoc analysis. No significant differences were found between genotypes for either pSMAD.
doi:10.1371/journal.pone.0018723.g005
High Nephron Number in the Mouse
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suggests that TGFb2 initially acts directly upon ureteric epithelium
to inhibit branching. Subsequent expression of betaglycan in
interstitial cell populations from e14.5 suggests that after this age,
TGFb2/betaglycan signalling is involved in the development of
both the epithelial and interstitial cell populations of the
metanephros.
Secondly, betaglycan and Tgfb2 mutant renal phenotypes share
several similarities. Like betaglycan
+/2, Tgfb2 heterozygotes
develop normally and possess more nephrons than wildtype mice
at PN30, displaying an even greater enhancement of nephron
number than betaglycan
+/2 mice [6,39]. This suggests that
TGFb2/betaglycan signalling is required to negatively regulate
nephrogenesis, possibly through the regulation of ureteric
branching morphogenesis. This observation is in agreement with
previous work that suggests abrogation of endogenous betaglycan
in vitro attenuates endogenous autocrine and/or paracrine TGFb-
mediated negative regulation of lung branching morphogenesis
[40]. In contrast to the renal phenotype in betaglycan
+/2 mice, in
vivo stereological analysis and in vitro culture of betaglycan
2/2
metanephroi revealed a hypoplastic renal phenotype that closely
resembled the defective development of Tgfb2 null explants [6].
These contrasting phenotypes in betaglycan
+/2 and betaglycan
2/2
kidneys suggest that the TGFb2/betaglycan signalling pathway
plays dual roles in vivo, both limiting the growth of the ureteric tree
while supporting the maintenance of the newly-formed nephrons.
The contrasting and complex renal phenotypes in betaglycan
+/2
and betaglycan
2/2 mice suggest that TGFb2/betaglycan signalling
is required at more than one stage of kidney development and in
more than one cell type, with specific developmental processes in
the kidney having higher thresholds for TGFb2 signalling than
others. Specifically, the data suggest that greater TGFb2 signalling
is necessary to limit early branching of the ureteric tree, and that
betaglycan is an essential component of the TGFb2 signalling
complex that allows critical thresholds of TGFb2 signalling to be
met during this process. In contrast, TGFb2-mediated survival of
ureteric epithelium during late gestation appears to occur at a lower
threshold of TGFb2 signalling. This conclusion is based on the
observation that newly-formed epithelial structures are maintained
when the level of either the ligand or the accessory receptor is
reduced, as in Tgfb2 heterozygotes or betaglycan
+/2 mice,
respectively. Conversely, ablation of TGFb2 signalling in Tgfb2
null metanephroi results in degeneration of these newly-formed
structures, an effect that could be hypothesized to be due to
insufficient pro-survival signalling attributed to TGFb2 [12,41,42].
As degeneration of renal tissues was not observed in betaglycan
2/2
metanephroi, this suggests that the relatively low, but still present
TGFb2 signalling in betaglycan
2/2 metanephroi is sufficient to
satisfy a threshold necessary for cell survival. This further suggests
that the processes of ureteric branching morphogenesis and cell/
tissue survival have differing TGFb2 concentration-dependent
signalling thresholds.
The betaglycan mutant phenotypes largely resemble their Tgfb2
mutant counterparts, suggesting that a major role for betaglycan in
the fetal murine kidney is as a determinant of TGFb2 efficacy.
Furthermore, the opposing phenotypes in both Tgfb2 and
betaglycan, null and heterozygote kidneys indicate that the
TGFb2/betaglycan signalling pathway has dose-dependent ac-
tions and that activity of this pathway must be tightly controlled
for normal branching morphogenesis and nephrogenesis to occur.
Molecular analysis of betaglycan mutant kidneys indicated that the
distinct morphological phenotypes in the betaglycan
+/2 and
betaglycan
2/2 kidneys were mirrored at the molecular level. In
particular, specific temporal changes in the expression of certain
TGFb superfamily members (for example Bmp4 during the
initiation of ureteric branching morphogenesis in betaglycan
+/2
metanephroi) may underlie the contrasting phenotypes. These
findings may be of considerable importance to human health in
that renal hypodysplasia is a recognized cause of paediatric renal
failure and a risk factor for hypertension in adults [43].
Materials and Methods
Animal Models
All animal handling and experimental procedures were approved
by the Monash Medical Centre Animal Ethics Committee (Study
approval ID B08/26). Wildtype, betaglycan
+/2 and betaglycan
2/2
embryos were obtained from timed matings of betaglycan
+/2 mice,
and genotyped as previously described [15,44]. Embryo develop-
ment was verified via Theiler staging criteria and the total number
of tail somites present from tail to hind limb [45]. Kidneys were
dissected from e11.5–e16.5 embryos, processed and fixed as
described below. To assess postnatal renal morphology, kidneys
were collected from wildtype and betaglycan
+/2 PN4, PN5, PN6
and PN30 mice, immersion-fixed in 10% neutral buffered formalin,
processed and embedded in paraffin wax. Sections (5 mm) were
stained with haematoxylin and eosin, periodic acid Schiff’s,
Masson’s trichrome or silver methenamine histological stains as
indicated, and assessed in a blind manner.
Wholemount and section immunolabelling
Metanephroi from wildtype embryos were fixed in 4%
paraformaldehyde at 4uC for 30 min, embedded in paraffin wax
and sectioned at 5 mm. Immunofluorescence detection was
conducted as previously described [44] using primary antibodies
against betaglycan (1:50, R&D Systems, MN, USA), phosphory-
lated (p)SMAD1 (1:100, Santa Cruz, CA, USA) or pSMAD3
(1:100, Abnova, NSW, Australia) in 1% BSA. Betaglycan
expression was detected using a donkey anti-goat Alexa Fluor
488-conjugated secondary antibody (1:400; Molecular Probes).
Quantitative assessment of pSMAD1 and pSMAD3 expression
was performed by counting positive cells in six non-overlapping
high-power (6400 magnification) fields per metanephric section.
Results are expressed as the percentage of pSMAD1 or pSMAD3
immunopositive cells per total number of metanephric cells.
For ureteric bud analysis, wholemount Calbindin D28k (Sigma-
Aldrich, NSW, Australia) immunofluorescence was performed, as
detailed by [46], on gonadal ridges isolated from e11.0 (14–17 tail
somites), e11.5 (18–22 tail somites) and e12.0 embryos (23–26 tail
somites) [45,47]. The presence and morphology of the ureteric
bud was correlated with the number of developing somites
observed. To assess in vitro development of the ureteric tree, whole
metanephroi from e12.5 embryos were cultured on polycarbonate
filters (3 mm pores) in wells containing serum-free Dulbecco’s
Modified Eagle’s Medium/Nutrient F-12 Ham culture medium
(350 ml; Sigma-Aldrich) at 37uC and 5% CO2, for 48 h. The
explants were processed for immunolabeling as above, using
antibodies against Calbindin D28K (1:200; secondary antibody -
Alexa Fluor 488 goat anti-mouse, Molecular Probes Inc., OR,
USA) and WT1 (1:100, Santa Cruz; secondary antibody - Alexa
Fluor 594 goat anti-rabbit) in combination to detect ureteric
epithelium and glomeruli, respectively. The total number of
ureteric branch points, branch tips and developing glomeruli were
quantified as previously described [6,48].
Estimation of nephron number in developing kidneys
To determine the total number of developing nephrons in
embryonic kidneys, metanephroi collected from e15.5 mouse
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paraffin wax and exhaustively sectioned at 5 mm. All sections were
blocked in 2% bovine serum albumin (BSA) in PBS with 0.3%
Triton-X for 30 mins at room temperature. Sections were then
digested with 0.1% neuraminidase (Sigma Aldrich) in 1% CaCl2 in
PBS, and incubated overnight at 4uC with biotinylated peanut
agglutinin (PNA; Sigma-Aldrich) diluted at 20 mg/ml in 2% BSA/
PBS and 0.3% Triton-X with 1 mmol/L CaCl2/MnCl2/MgCl2.
Following incubation, sections were rinsed twice with PBS. The
biotinylated PNA was visualized using the Elite streptavidin/biotin
amplification ABC kit (Vector Laboratories Inc., Burlingame, CA,
USA). The ABC solution was applied for 1 hour at room
temperature, after which slides were washed and the stain
developed with diaminobenzidine (DAB; Sigma Aldrich)/0.01%
H2O2/PBS. Sections were counterstained with haematoxylin.
Section pairs were used to estimate PNA-positive developing
nephrons using the physical disector/fractionator combination
[49]. PNA-positive structures (which included all developing
nephrons from early S-shaped bodies to developing glomeruli)
were marked in the first (n) section. The nth+5 section was then
viewed, with positive structures present in nth and not the nth+5
section counted. Those counted in the nth+5 section and not in the
nth section were also counted to double the efficiency of the
technique. This process was repeated with the first nominated
nth+5 section denoted the nth section and a new nth+5 section
selected. Total number of developing nephrons was determined as
the total number of PNA-positive structures observed (Cullen-
McEwen et al., submitted).
Estimation of ureteric epithelial volume
Ureteric epithelial volume was determined in e13.5 metaneph-
roi. Paraffin-embedded metanephroi were exhaustively sectioned
at 5 mm, after which all sections were dewaxed, rehydrated and
blocked in 2% BSA in PBS with 0.3% Triton-X for 30 min at
room temperature. Sections were then incubated overnight at 4uC
with biotinylated dolichos biflorus (DBA; Sigma-Aldrich). DBA-
positive structures were visualized using the Elite streptavidin/
biotin amplification ABC kit (Vector Laboratories Inc, CA, USA).
Unbiased stereology was then used to determine total and relative
epithelial volumes, as well as total metanephric volumes [46].
Estimation of total nephron number at PN30
Total nephron number was determined in female betaglycan
heterozygous and wildtype kidneys at PN30. Body weights were
recorded and kidneys dissected, cleaned of fat and blood vessels,
decapsulated and weighed. Kidneys were immersion-fixed in 10%
neutral buffered formalin, and processed for embedding in
glycolmethacrylate. Kidney volume, total glomerular number,
mean and total glomerular and mean and total renal corpuscle
volumes were estimated as described previously [6,49,50], with
total nephron number estimated using the unbiased physical
disector/fractionator combination.
Quantitative real-time PCR
Total RNA was isolated from pooled e11.5–e14.5 metanephroi
and complementary DNA was synthesized as previously described
[51]. All findings were observed across four separate, indepen-
dently collected pools of kidneys for each genotype and age (n=4–
6/pool). Real-time PCR was performed using the Applied
Biosystems ABI 7900 HT Fast real-time machine with all reactions
performed in triplicate. Yields were converted to femtograms and
normalized to the 18S mRNA level per sample, as previously
described [51]. Primers and their optimized annealing tempera-
Table 3. Table of primer sequences.
Gene
Name
Gene Bank
Number Primer Sequence (59 –3 9)
Product Size
(bp)
Annealing
Temperature (6C)
Bmp4 NM_007554 Forward AGGAGGAGGAGGAAGAGCAG
Reverse GAGGAAACGAAAAGCAGAGC
149 61
Ret NM_001080780 Forward TAAAGCAGGCTACGGCATCT
Reverse GTGGTGGCAGACACAGAAGA
172 61
Eya1 NM_010164 Forward ACAAGTCAGGCGGTCACAG
Reverse CCAGGTCCCAGATGAACACT
193 61
Gdnf NM_010275 Forward AATGTCCAACTGGGGGTCTA
Reverse GCCGAGGGAGTGGTCTTC
180 55
Pax2 NM_011037 Forward CTGCCCACATTAGAGGAGGT
Reverse TGGAAGACATCGGGATAGGA
199 55
Six1 NM_009189 Forward AACCCCTACCCCTCACCG
Reverse AGAGAGTTGATTCTGCTTGTT
177 55
Tgfb1 NM_011577.1 Forward AGCCCGAAGCGGACTACTAT
Reverse TTCCACATGTTGCTCCACAC
215 55
Tgfb2 NM_009367 Forward TTTAAGAGGGATCTTGGATGGA
Reverse AGAATGGTCAGTGGTTCCAGAT
197 55
Tgfb3 NM_009368 Forward CGCACAGAGCAGAGAATTGA
Reverse GTGACATGGACAGTGGATGC
204 55
Wnt4 NM_009523 Forward CCGGGCACTCATGAATCTT
Reverse ACGTCTTTACCTCGCAGGAG
113 61
Wt1 NM_144783 Forward GAGAGCCAGCCTACCATCC
Reverse CAACTGTCAGTAGGGGTGTGG
212 61
18s NR_003278.1 Forward GTAACCCGTTGAACCCCATT
Reverse CCATCCAATCGGTAGTAGCG
151 61
doi:10.1371/journal.pone.0018723.t003
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denaturation at 95uC, then 55 cycles of denaturing (95uC for
15 sec), annealing (5 sec) and elongation (72uC for 8 sec and 79uC
for 8 sec). PCR products were detected at 16–30 cycles. All PCR
products were initially verified by sequencing.
Statistical analysis
Unpaired Student’s t-tests, one-way or two-way ANOVAs, and
Tukey’s post-hoc analyses were conducted using GraphPad
Prism
TM 5 (Software Inc, 1992–2007). Values are mean 6 SD.
A probability of 0.05 or less was accepted as statistically significant.
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